Susceptibility patterns and molecular identification of Trichosporon species by Rodriguez-Tudela, Juan Luis et al.
 
   
 
 
This is the peer reviewed version of the following article: 
 
Susceptibility patterns and molecular identification of Trichosporon species. 
Rodriguez-Tudela JL, Diaz-Guerra TM, Mellado E, Cano V, Tapia C, Perkins A, Gomez-
Lopez A, Rodero L, Cuenca-Estrella M. 
Antimicrob Agents Chemother. 2005 Oct;49(10):4026-34. 
 













Running title: Identification of clinically relevant Trichosporon spp.   
 
Susceptibility Patterns and Molecular Identification of Trichosporon Species  
Juan L. Rodriguez-Tudela 1(*), Teresa M. Diaz-Guerra 1, Emilia Mellado 1, Virginia Cano 2, Cecilia Tapia 3, 
Alexander Perkins1, Alicia Gomez-Lopez 1, Laura Rodero 2 and Manuel Cuenca-Estrella 1 
(1): Servicio de Micología, Centro Nacional de Microbiología, Instituto de Salud Carlos III. Spain 
(2): Departamento Micología. Instituto Nacional de Enfermedades Infecciosas. ANLIS “Dr. Carlos G. Malbrán”. 
Argentina  
(3): Programa de Microbiología y Micología, ICBM, Facultad de Medicina, Universidad de Chile, Chile 
Keywords: Trichosporon spp, Internal Transcribed Spacer Regions, Intergenic Transcribed Spacer 
Region, Amphotericin B resistance  
 
(*): Corresponding author. Mailing address: 
Servicio de Micología, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Ctra Majadahonda-
Pozuelo Km 2. 28220 Majadahonda (Madrid), Spain.  
Phone: + 34-91-82236611. Fax: + 34-91-5097966.  
E-mail: juanl.rodriguez-tudela@isciii.es  
 
ABSTRACT 
The physiological patterns, the sequence polymorphisms of the internal transcriber spacer (ITS) and intergenic 
spacer regions (IGS) of the ribosomal DNA, and the antifungal susceptibility profile were evaluated for their 
ability and specificity in the identification of 49 clinical isolates of Trichosporon spp. Morphological and 
biochemical methodology was unable to identify seven species and other were misidentified frequently. ITS 
sequencing was also unable to differentiate several species. However IGS1 sequencing identified unambiguously 
all Trichosporon isolates.  
Following the results of DNA-based identification, T. asahii was the species most frequently isolated from deep 
sites (15/25 strains, 60%). In the main, other Trichosporon species were recovered from cutaneous samples. 
The majority of T. asahii, T. faecale and T. coremiiforme clinical isolates exhibited resistance in vitro to 
amphotericin B, with geometric means (GM) of MICs > 4 µg/ml. The other species of Trichosporon did not show 
high MICs of amphotericin B and GMs were < 1µg/ml. Azole agents were active in vitro against the majority of 
clinical strains. The most potent compound in vitro was voriconazole, with GM < 0.14 µg/ml.  
The sequencing of IGS identified correctly Trichosporon isolates, however, this technique is not available in 
many clinical laboratories and strains should be dispatched to reference centers where these complex methods 
are available. Therefore it seems more practical to perform antifungal susceptibility testing to all isolates 
belonging to Trichosporon spp. since correct identification could take several weeks delaying the indication of 
an antifungal agent, which exhibits activity against the infectious strain.  
 
INTRODUCTION 
The number of species of yeasts pathogenic for humans reported in the literature has greatly increased in recent decades. 
This increase is a consequence of the rise of hosts presenting factors, which predispose them to fungal infections such as 
cytotoxic chemotherapy, neutropenia, broad spectrum antibiotic treatment, steroids and invasive catheterization. In 
these situations almost all yeasts are potential pathogens (10,32).  
Trichosporon species are causative agents of cutaneous infections and are involved in systemic, localized or disseminated 
mycoses, particularly in patients with underlying hematological malignancy, AIDS, burns and solid tumors (3,12,21). 
Likewise, non-immunosuppressed patients have suffered from Trichosporon infections associated with ophthalmologic 
surgery, infections of prosthetic devices, intravenous drug abuse, and peritoneal dialysis (16,20).  
It was thought that there was only one species of Trichosporon and that it was most appropriately called Trichosporon 
beigelii. However, the genus Trichosporon has recently undergone extensive taxonomic reevaluation and a rearrangement 
of the genus has been proposed. Several morphologic and biochemical patterns were recognized among clinical and 
environmental isolates, and ultraestructural and DNA studies confirmed those findings, being T. beigelii split in a number 
of distinct species (13,14,17). So far, the genus Trichosporon includes seven species associated with human infections: 
Trichosporon asahii, Trichosporon asteroides, Trichosporon cutaneum, Trichosporon inkin, Trichosporon jirovecii, 
Trichosporon mucoides, and Trichosporon ovoides. T. asahii appears to be much more common in cases of systemic 
mycosis while other Trichosporon species are involved in superficial skin lesions (2). In addition, differences per species in 
their antifungal susceptibility profile have been reported as well (23).  
The identification of these fungal pathogens by conventional methods is often difficult and inconclusive frequently. DNA-
based molecular procedures can provide alternative and more useful methods for characterization and identification of 
Trichosporon spp. (26,28,30). In this study, the morphologic and biochemical patterns, the sequence polymorphisms of 
the internal transcriber spacer 1 and 2 regions (ITS1 and ITS2), the intergenic spacer 1 (IGS1) of the ribosomal DNA, and 
the antifungal susceptibility profile were evaluated for their ability and specificity in the identification of a collection of 
49 clinical isolates of Trichosporon spp. 
MATERIAL AND METHODS 
 
Fungi 
Clinical strains. A collection of 49 clinical isolates was included in the study. All strains were recovered from 42 Spanish 
and Argentinean hospitals through a period of ten years, from 1993 to 2002. The isolates were obtained from a variety of 
clinical sources as they are displayed in table 1. Twenty-four strains were isolated from superficial sites and 25 from deep 
sites including eight blood cultures, five respiratory tract samples and three urines. Each isolate was obtained from a 
different patient. The isolates were sent to Mycology Reference Laboratory of National Center for Microbiology of Spain 
for identification and susceptibility testing.  
Reference strains and sequences obtained from the GenBank database. Table 2 shows the list of 
Trichosporon strains used for comparative analysis of the ITS and IGS sequences.  
Outgroup strains. Sequences of ITS and IGS of Cryptococcus neoformans (CBS 131 No. Acc. GenBank 
AJ300916) and C. neoformans var. gattii (CBS 6956 No. Acc. GenBank AJ300920) were used as outgroups. 
Morphological and biochemical identification 
The clinical strains were subcultured on 4% malt extract/0.5% yeast extract agar (MEYA). After 10 days at 
30ºC, macroscopic and microscopic examinations were done. The isolates were identified by routine 
physiological tests: fermentation of and growth on carbon sources, growth on nitrogen sources, growth at 
various temperatures and ability for hydrolyzing urea (2,7,14). Table 3 displays the distinctive characteristics 
per species of Trichosporon. Biochemical and morphological characterizations were done according to data 
depicted in references 2, 7 and 14. For T. dermatis the biochemical characteristics were obtained from reference 
31 (31). 
PCR and DNA sequencing of ITS and IGS regions  
Yeasts were cultured in YEPD medium (1% yeast extract, 2% peptone, 2% dextrose, OXOID, Madrid, Spain), 
for 24-48 h at 150 rpm at 30ºC. One ml of the medium was centrifuged at 13.000 rpm for 10 minutes. The 
pellet was suspended in 1 ml of cold SE buffer (20 mM citrate-phosphate buffer pH: 5.6, 50 mM EDTA, 0.9 
sorbitol) and centrifuged under the same conditions. This process was repeated twice. A small quantity of glass 
pearls was added together with 50 µl of lysis buffer (50 mM Tris- HCl pH: 7.2, 50 mM EDTA, 3% sodium dodecyl 
sulphate). The mixture was vortexed at low speed for at least 15 seconds. Lysis buffer (400 µl and 4 µl of beta-
mercaptoethanol (final concentration 1%, Sigma-Aldrich Química) were added, and the mix incubated at 65ºC 
 
for 2 hours. The blend was gently mixed every 30 minutes. DNA was then purified by repeated phenol-
chloroform-isoamilic (25:24:1) extractions, ethanol precipitation and RNAase treatment. Finally, DNA 
concentration was estimated comparing the bands obtained from each sample with the bands of known amounts 
of lambda phage DNA in a 0.8% agarose gel (Pronadisa, Madrid, Spain). DNA was purified using Chroma Spin 
+ TE 200 columns from (Clontech Laboratories, Inc, Becton Dickinson, Madrid, Spain). 
DNA segments comprising the region ITS1 and ITS2 were amplified with primers ITS1 (5` 
TCCGTAGGTGAACCTGCGG 3`) and ITS4 (5`TCCTCCGCTTATTGATATGC 3`) (34). DNA segments comprising 
the region IGS1 were amplified with primers 26SF (IGS1-26SS) (5` ATCCTTTGCAGACGACTTGA 3`) and 5SR 
(IGS2-58S) (5` AGCTTGACTTCGCAGATCGG 3`)(26). Reaction mixtures contained 0.5 µM of each primer, 0.2 
mM of each dNTP, 5 µl of PCR buffer 10X (Applied Biosystem, Madrid, Spain), 2.5 U Taq DNA polimerase 
(Amplitaq, Applied Biosystem) and 25 ng of DNA in a final volume of 50 µl. The samples were amplified in a 
GeneAmp PCR System 9700 (Applied Biosystem) using the following cycling parameters: one initial cycle of 2 
min at 94ºC, followed of 35 cycles of 30 sec at 94ºC, 45 sec at 56ºC, and 2 min at 72ºC, and one final cycle of 
5 min at 72ºC. The reaction products were analyzed in a 0.8 % agarose gel.  
Sequence reactions were done using 4 µl a DNA sequencing kit (BigDye Terminator Cycle Sequencing Ready 
Reaction, Applied Biosystem), 1 µM of the primers (ITS1, ITS4, 26SF and 5SR) and 3 µl of the PCR product in 
a final volume of 10 µl. Sequences were assembled and edited using the SeqMan II and EditsEq software 
packages (DNAstar, Inc. Lasergene, Madison, USA). The sequence analysis was performed by comparison with 
the nucleotide sequences of Trichosporon reference isolates obtained from the GenBank database 
(http://www.ncbi.nih.gov/Genbank/) and from sequences of reference strains from the CBS (Centraalbureau 
voor Schimmelcultures, Delft, The Netherlands). Those strains are displayed in table 2. 
 
Phylogenetic Analyses 
All phylogenetic analyses were conducted with Fingerprinting II informatix software version 3.0 (BIORAD 
laboratories, Madrid, Spain). The methodology used was maximum parsimony clustering. Phylogram stability 
was assessed via parsimony bootstrapping with 1000 simulations. Phylograms were outgroup rooted with 
Cryptococcus neoformans (CBS 132) and C. neoformans var. gattii (CBS 6956). 
Antifungal susceptibility testing 
The susceptibility testing followed strictly the recommendations proposed by the Antifungal Susceptibility Testing 
Subcommittee of the European Committee on Antibiotic Susceptibility Testing for testing fermentative yeasts 
(AFST-EUCAST, discussion document 7.1) (24). These recommendation are based on NCCLS procedure 
described in M27-A2 document (22), but including some modifications in order to allow for automation of the 
susceptibility method and to permit the incubation period to be shortened from 48 to 24 h. Briefly, the 
susceptibility testing included RPMI supplemented with 2% glucose as assay medium, inoculum size of 105 
CFU/ml, flat-bottomed trays, and spectrophotometric reading. In order to improve the growth a minor 
modification was include (25). That was, all microplates were wrapped with film sealer to prevent the medium 
from evaporating, attached to an electrically driven wheel inside the incubator, agitated at 350 rpm and 
incubated at 30ºC for 48 hours. Candida parapsilosis ATCC22019 and Candida krusei ATCC6258 were used as 
quality control strains.  
The antifungal agents used in the study were as follows: Amphotericin B (Sigma Aldrich Quimica S.A., Madrid, 
Spain), 5-flucytosine (Sigma Aldrich Quimica), fluconazole (Pfizer S.A, Madrid, Spain), itraconazole (Janssen 
S.A., Madrid, Spain) and voriconazole (Pfizer S.A.,). The MICs were determined at 24 and 48 h. MICs were 
obtained measuring the absorbance at 530 nm with a MRXII reader (Dynatech, Cultek, Madrid, Spain). For AMB 
the MIC endpoints were defined as the lowest drug concentration exhibiting reduction in growth of 90% or more 
compared with that of the control growth. For flucytosine and azole drugs the MIC endpoint was defined as 
50% of inhibition. 
 
RESULTS 
Morphological and biochemical identification 
Table 1 includes the identification of clinical isolates tested obtained by morphological and biochemical methods. 
Table 3 shows the differential morphological and biochemical characteristics of Trichosporon species. Sixteen 
strains were identified as T. mucoides, fifteen as T. asahii, eleven as T. inkin, four as T. cutaneum, and three 
as T. ovoides.  
Molecular identification 
The genetic relatedness of 49 clinical strains (table 1) together with reference strains and nucleotide sequence 
data obtained form GeneBank included in table 2 were analyzed. Aligned complete sequences of the IGS1, and 
ITS1 and ITS2 were analyzed phylogenetically using two strains of C. neoformans (CBS 132 and 6956 
respectively) to root the trees.  
Maximum parsimony analysis of ITS sequences did not resolve adequately Trichosporon species as figure 1 
shows. Three clades were identified that can be consulted in table 1. Clade I had a maximum of 8 base 
conversions and clade III a maximum of 3 base conversion. As an exception, in clade II, T. sporotrichoides. T. 
brasiccae and, T. veenhuisii were resolved. However, there is only one sequence for each species and therefore 
any conclusion cannot be obtained. The rest of species including in this clade have a maximum of 5 base 
conversions. 
  
Maximum parsimony analysis of IGS sequences resolved adequately all Trichosporon species. Figure 2 shows a 
rooted cladogram with all clinical isolates and the respective reference strains or sequences from GeneBank 
included in this study. Those species without clinical isolates are not included in the cladogram, although they 
were unambiguously differentiated. Therefore, each clinical isolate was considered to belong to the species that 
maximum parsimony analysis of IGS sequences indicated. Table 1 contains the final identification of clinical 
strains. Thus, the 49 clinical isolates were identified as follows: fifteen T. asahii, eight T. dermatis, seven T. 
inkin, five T. ovoides, four T. faecale, two T. coremiiforme, two T. cutaneum, two T. jirovecii, two T. japonicum, 
one T. montevideense and, one T. domesticum. Notably, all T. asahii were isolated from deep samples while 
other species were more frequently associated with superficial sources (100% vs 29.4%; table 1). As exceptions, 
 
one T. faecale isolated from a catheter, two T. coremiiforme from urine and a subcutaneous abscess, two T. 
inkin from a bone biopsy and a subcutaneous abscess, one T. ovoides from peritoneal fluid, one T. jirovecii from 
urine, one T. japonicum from pleural fluid and two T. dermatis from subcutaneous abscess and blood culture 
respectively. The last two species T. japonicum and T. dermatis have not been associated with human samples 
before but in this study were detected twice and seven times, respectively.  
Discrepancies among molecular and morphological and biochemical identification 
Table 4 shows the discrepancies among molecular and morphological and biochemical identification. 
Morphological and biochemical methods were unable to identify the following species: T. dermatis, T. faecale, 
T. coremiiforme, T. jirovecii, T. japonicum, T. montevideense and T. domesticum (table 4). In addition T. asahii, 
T. ovoides and T. cutaneum were misidentified most of the times as other Trichosporon species (table 4). As 
an exception, T. inkin was correctly identified by classical methodology 6 out 7 times (Table 4).  
Antifungal susceptibility testing 
Susceptibility results are showed in table 4. Table displays geometric means (GM) and ranges of MICs, per 
antifungal agent and grouped per Trichosporon spp. and per identification procedure. According to DNA-based 
identification, it should be stressed that the majority of T. asahii, T. faecale and T. coremiiforme clinical isolates 
exhibited resistance in vitro to amphotericin B, with GM of MICs >4.0 µg/ml. Only one isolate of T. faecale had 
an amphotericin B MIC of 0.25 µg/ml while the rest had MICs > 2 µg/ml. The other species of Trichosporon did 
not show high MICs of amphotericin B and GMs were < 1.0 µg/ml. In addition, all eleven species exhibited high 
MICs of flucytosine, and most isolates were resistant in vitro, with MICs over 16.0 µg/ml. On the contrary, azole 
agents were active in vitro against the majority of clinical strains, independently of species of Trichosporon 
analyzed. The most potent compound in vitro was voriconazole, with GM < 0.14 µg/ml.  
 
Four strains of T. asahii (4/15, 26.6%) and three isolates of T. dermatis (3/8, 37.5%) exhibited MICs of 
fluconazole as high as 32.0-64.0 µg/ml. Five of those strains (two T. asahii and all T. dermatis) showed higher 
MICs of itraconazole (> 2.0 µg/ml) and voriconazole (> 8.0 µg/ml) as well.  
 
 
There were differences in antifungal susceptibility were found when MICs were analyzed per isolation site (deep 
vs. superficial isolates). Thus, the strains isolated form deep samples had higher MICs to all antifungals except 
for flucytosine. The most significant difference was found among the MICs of amphotericin B. Hence, the GM of 
amphotericin B of strains isolated from deep samples were 2.7 g/ml and from superficial sources 0.3 µg/ml. 
 
DISCUSSION 
The identification of yeasts is based largely on physiological and biochemical characteristics. The tests most 
used for routine identification purposes are fermentation of and growth on carbon sources, growth on nitrogen 
sources, requirements of vitamins, growth at various temperatures, hydrolysis of urea and resistance to 
antibiotics (2,14). The combined used of biochemical characteristics and direct observation of fungal structures 
under a light microscope permits the identification of species causing the majority of human infections. However, 
the number of new species of opportunistic yeasts causing mycoses has increased during the past two or three 
decades, making the identification by conventional methods more difficult, even having expertise in Mycology 
(19). In addition, conventional identification by the evaluation of morphological and biochemical characteristics 
can be laborious, leading to inconclusive or presumptive identifications, particularly for infrequent pathogenic 
species.  
In order to overcome these drawbacks, several groups have designed molecular procedures for identifying 
yeasts. One of the main advantages of molecular methods is their sensitivity and specificity, being fully 
discriminative even for species closely related (7). The majority of molecular methods are PCR-based techniques 
using either specific probes or universal fungal primers, normally directed to conserved regions of ribosomal 
DNA, particularly towards the ITS regions (4-6). The identification using ITS regions must include a subsequent 
analysis such as sequencing or restriction fragment length polymorphism analysis. This approach has been put 
into practice in clinical laboratories for rapid detection and identification of yeasts found in positive blood 
cultures, being evaluated as a promising diagnostic tool (11,18).  
Sugita et al have developed procedures based on ITS regions for identification of Trichosporon spp. These 
procedures are capable of characterizing the majority of species of Trichosporon, including those pathogenic for 
humans (26,28,30). The results obtained with these techniques have led to reclassify both clinical and 
environmental isolates of these species, design a nested PCR assay to detect DNA in sera for the diagnosis of 
deep-seated trichosporonosis, describe the first bloodstream infection due T. asteroides and associate T. ovoides 
with hypersensitivity pneumonitis (15,27-29). Recently, DNA-based procedures for identification of Trichosporon 
have been stepped up by the sequence analysis of the ribosomal DNA intergenic spacer 1 regions (IGS) which 
 
provides a more powerful and alternative method to distinguish between phylogenetically closely related species 
(26).  
 
The data presented in this work suggest that morphological and biochemical methodology is not an useful and 
reliable method for Trichosporon identification. This methodology was unable to identify seven species and 
others were misidentified frequently (table 4). On the other hand, sequencing of DNA fragments seems to be a 
better approach for identification to species level of this genus. However, ITS sequencing was also unable to 
differentiate several species as unrooted cladogram of figure 1 shows. Therefore, three clades were established. 
Clade I comprised T. cutaneum, T. dermatis, T. jirovecii, T. moniliforme and T. mucoides; clade II, T. brasiccae, 
T. domesticum, T. dulcitum, T. gracile, T. laibachii, T. loubieri, T. montevideense, T. sporotrichoides and T. 
veenhuisii, and clade III, T. asahii, T. asteroides, T. coremiiforme, T. faecale, T. inkin, T. japonicum and T. 
ovoides. Furthermore, looking at sequences (data not shown) there are very few differences among the ITS 
sequences of each clade and therefore it is hazardous to assume the identification to level species based on this 
DNA fragment.  
IGS sequences identified unambiguously all Trichosporon isolates as Figure 2 shows. For some species as T. 
jirovecii, T. dermatis. T. inkin, T. faecale and, T. asahii, polymorphisms were detected in IGS sequences. Further 
experiments with more strains are required to ascertain if those polymorphisms can be used for genotyping. 
However, there are preliminary evidences of the existence of five genotypes when IGS sequences of T. asahii 
were analyzed (26). In this work, T. asahii was also divided in 5 types supporting the results obtained by Sugita 
et al (26). 
 
A second area to consider is the antifungal susceptibility testing of Trichosporon spp. A 1990 study defined T. 
beigelii as an emerging pathogen resistant to this antifungal compound (33). After the taxonomic reevaluation, 
it has been proven that T. asahii is more resistant in vitro to amphotericin B than to triazole compounds (1,23). 
These data in vitro has been corroborated by results in vivo and successful outcomes with treatments with 
voriconazole have been documented in some cases of deep infections due to this species that did not respond 
to amphotericin B therapy (8,9,35). On the contrary, the non-T. asahii species appear more resistant to triazole 
 
agents than amphotericin B (23), although these data have not been proven in vivo. Our results confirmed that 
T. asahii is resistant in vitro to amphotericin B because all isolates exhibited amphotericin B MICs > 2.0 µg/ml. 
In addition, T. faecale and T. coremiiforme seem to be also in vitro resistant to amphotericin B because all 
except one of the isolates included in this study had MICs > 2.0 µg/ml. These two species are considered by 
some authors varieties of T. asahii (14). The other Trichosporon species were susceptible in vitro to the polyene. 
 With regard to azole agents, resistance in vitro to fluconazole was found in a minority of T. asahii and T. 
dermatis isolates, being the remaining isolates susceptible in vitro, although a number of fluconazole MICs were 
of 4.0-8.0 µg/ml . Itraconazole and voriconazole were the most potent agents in vitro against all Trichosporon 
spp., particularly voriconazole with GM of MICs under 0.14 µg/ml, confirming that these compounds can be 
useful in treating these infections. 
 
This work shows that biochemical and morphological identification and ITS sequencing are not reliable 
techniques for Trichosporon spp. identification as they were unable to distinguish between species. Correct 
characterization of these species can be significant at therapeutic level in view of their distinct antifungal 
susceptibility profile, particularly for T. asahii, which is highly resistant to amphotericin B. The sequencing of 
IGS identified correctly Trichosporon isolates, however, this technique is not available in many clinical 
laboratories and strains should be dispatched to reference centers where these complex methods are available. 
Therefore it seems more practical to perform antifungal susceptibility testing to all isolates belonging to 
Trichosporon spp. since correct identification could take several weeks delaying the indication of an antifungal 
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